VIR-5500 (AMG 509)
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 1Active (Astellas Collab)
Key Facts
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase
Phase 1
Status
Active (Astellas Collab)
Company
About Vir Biotechnology
Vir Biotechnology is a San Francisco-based immunology company with a mission to power the immune system to transform patient lives. Founded in 2016, the company has rapidly validated its technology platforms through successful COVID-19 and Ebola programs and is now strategically focused on high-unmet-need areas, including chronic hepatitis delta and select oncology indications. Its strategy combines deep immunology expertise with advanced antibody engineering to create differentiated, rapidly deployable clinical candidates.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tomivosertib | eFFECTOR Therapeutics | Phase 2 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| AB-3028 | Arsenal Biosciences | IND-Enabling |
| PRO CAR-201A | PromiCell | Phase 1 |
| PRO CAR-202 | PromiCell | Preclinical |
| FG-3246 | Kyntra Bio | Phase 2 |
| PROVENGE (sipuleucel-T) | Dendreon | Approved |
| RP12146 | Rhizen Pharmaceuticals | Phase 1b |
| Monoclonal Antibody (undisclosed) | MetaCurUm Biotech | Preclinical |
| ModraDoc006/r | Modra Pharmaceuticals | Phase 2b |
| SYNC-T | Syncromune | Phase 2 |
| Gedatolisib | Celcuity | Phase 3 Planned |